Dimensional Fund Advisors’s Entrada Therapeutics TRDA Stock Holding History

Dimensional Fund Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.77M	Buy	376,136 +51,665	+16%	+$495K	﹤0.01%	2665
2026 Q1	$4.09M	Buy	324,471 +51,093	+19%	+$586K	﹤0.01%	2557
2025 Q4	$2.81M	Sell	273,378 -120,901	-31%	-$1.02M	﹤0.01%	2664
2025 Q3	$2.29M	Sell	394,279 -29,706	-7%	-$174K	﹤0.01%	2738
2025 Q2	$2.85M	Buy	423,985 +96,858	+30%	+$779K	﹤0.01%	2667
2025 Q1	$2.96M	Buy	327,127 +110,121	+51%	+$1.37M	﹤0.01%	2627
2024 Q4	$3.75M	Buy	217,006 +121,598	+127%	+$2.2M	﹤0.01%	2620
2024 Q3	$1.53M	Buy	+95,408	New	+$1.5M	﹤0.01%	2840

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Dimensional Fund Advisors's TRDA Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Entrada Therapeutics (TRDA) stake by 16% in Q2 2026, buying an estimated $495K and bringing the position to 376,136 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2665.

Dimensional Fund Advisors first reported a position in TRDA in Q3 2024 and has held it in 8 quarters since. The position peaked at $4.09M in Q1 2026. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Dimensional Fund Advisors held 376,136 shares of Entrada Therapeutics worth $2.77M as of Q2 2026.
Dimensional Fund Advisors bought 51,665 Entrada Therapeutics shares in Q2 2026, an estimated $495K.
Entrada Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2665 holding.
Dimensional Fund Advisors first reported a position in Entrada Therapeutics in Q3 2024 and has held it in 8 quarters since.
Dimensional Fund Advisors's Entrada Therapeutics position peaked at $4.09M in Q1 2026.
129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.